NASDAQ:HCAT - Nasdaq - US42225T1079 - Common Stock - Currency: USD
/PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare...
The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Health Catalyst (HCAT) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: NYXH
SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics...
/PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare...
SALT LAKE CITY, April 17, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (
/PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare...
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
From commerce to culture, software is digitizing every aspect of our lives. This secular theme has materialized in superior earnings growth and stock price performance for most SaaS companies, and over the last six months, the industry’s 14.2% return has topped the S&P 500 by 9.2 percentage points.
/PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare...
Healthcare software provider Health Catalyst (NASDAQ:HCAT) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 6% year on year to $79.61 million. On the other hand, next quarter’s revenue guidance of $79 million was less impressive, coming in 3.5% below analysts’ estimates. Its non-GAAP profit of $0.04 per share was 47.6% below analysts’ consensus estimates.
SALT LAKE CITY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2024.